3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Thrombocytopenia
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neutropenia
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphopenia
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Graft vs Host Disease
1
Cytopenia
1
Anemia
1
Interventions
ruxolitinib
28
navitoclax
6
Azacitidine
5
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
4
parsaclisib
3
luspatercept
3
itacitinib
3
givinostat hydrochloride
3
givinostat
3
fedratinib
3
INCB039110
3
selinexor
2
pomalidomide
2
imetelstat
2
bomedemstat
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
LY2784544
2
INCB057643
2
GRN163L peptide
2
venetoclax
1
triciribine
1
tagraxofusp
1
spartalizumab
1
sonidegib
1
simtuzumab
1
sabatolimab
1
rucaparib
1
ridaforolimus
1
quizartinib
1
pelcitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Primary Myelofibrosis
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled